Personalization of molecular targeted therapies
We developed imaging methodologies that improved understanding of tumor growth and its microenvironment (NIH CA136927 R01 grant). We have shown that the hypoxia map estimated from dynamic FMISO (18F-fluoromisonidazole) PET study correlates with MRI studies of hypoxia, while simultaneous FMISO-PET and MRI imaging improves biological tumor characterization and allows for individualization of treatment strategies . We explained the physiology of anti-angiogenic therapy and related changes in tumor cell proliferation and vasculature through kinetic analysis of dynamic 18F-FLT (3′-deoxy-3′-18F-fluorothymidine) PET imaging. We have also shown that microscopic tissue properties that can be identified through texture metrics in PET images can differentiate between responders and non-responders to immunology treatment in non-small-cell lung cancer.